Wells Fargo
AMLX icon

Wells Fargo’s Amylyx Pharmaceuticals AMLX Stock Holding History

Wells Fargo’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
128,164
+53,081
+71% +$821K ﹤0.01% 3477
2026
Q1 		$1.04M Sell
75,083
-71,226
-49% -$1M ﹤0.01% 3713
2025
Q4 		$1.77M Buy
146,309
+52,618
+56% +$715K ﹤0.01% 3540
2025
Q3 		$1.27M Buy
93,691
+55,590
+146% +$523K ﹤0.01% 3645
2025
Q2 		$244K Buy
38,101
+37,801
+12,600% +$184K ﹤0.01% 4657
2025
Q1 		$1.06K Hold
300
– – ﹤0.01% 6235
2024
Q4 		$1.13K Hold
300
– – ﹤0.01% 6247
2024
Q3 		$972 Hold
300
– – ﹤0.01% 6128
2024
Q2 		$570 Sell
300
-20,649
-99% -$40K ﹤0.01% 6137
2024
Q1 		$59.5K Sell
20,949
-13,316
-39% -$174K ﹤0.01% 5178
2023
Q4 		$504K Sell
34,265
-11,076
-24% -$170K ﹤0.01% 3866
2023
Q3 		$830K Sell
45,341
-12,154
-21% -$257K ﹤0.01% 3456
2023
Q2 		$1.24M Buy
57,495
+35,545
+162% +$960K ﹤0.01% 3302
2023
Q1 		$644K Buy
21,950
+20,231
+1,177% +$703K ﹤0.01% 3679
2022
Q4 		$63.5K Buy
1,719
+762
+80% +$27K ﹤0.01% 4756
2022
Q3 		$27K Sell
957
-621
-39% -$15.5K ﹤0.01% 5240
2022
Q2 		$30K Sell
1,578
-88,246
-98% -$1.05M ﹤0.01% 5266
2022
Q1 		$1.16M Buy
+89,824
New +$2.03M ﹤0.01% 3756

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Wells Fargo's AMLX Position: Q2 2026 in Review

Wells Fargo increased its Amylyx Pharmaceuticals (AMLX) stake by 71% in Q2 2026, buying an estimated $821K and bringing the position to 128,164 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3477.

Wells Fargo first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Wells Fargo held 128,164 shares of Amylyx Pharmaceuticals worth $2.3M as of Q2 2026.
  • Wells Fargo bought 53,081 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $821K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3477 holding.
  • Wells Fargo first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.